Gene · 5277
Papers1,372
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,372
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study. | Ann Hematol | 2026 | 41566054 | PubTator, text mining | PubMed |
| Paroxysmal nocturnal hemoglobinuria presenting with acute kidney injury in an 18-year-old male: a case report. | Korean J Fam Med | 2026 | 41437524 | PubTator, text mining | PubMed |
| PIGA variants are associated with focal epilepsy with favorable outcome and the sub-molecular effect. | Seizure | 2026 | 41352325 | PubTator, text mining | PubMed |
| A 14-year multicentric follow-up study of atypical pemphigus variants in Italy: the VARIANT_P study. | Clin Exp Dermatol | 2026 | 41072932 | PubTator, text mining | PubMed |
| High-Content Screening of Wind-Dampness Dispelling Traditional Chinese Medicines against Podocyte EMT Induced by IgA1. | Comb Chem High Throughput Screen | 2026 | 40304343 | PubTator, text mining | PubMed |
| Gene replacement therapy for Piga GPI-anchor deficiency in the developing nervous system. | bioRxiv | 2025 | 41415370 | PubTator, text mining | PubMed |
| Case report: Spontaneous remission of severe aplastic anemia mediated by mutant hematopoietic stem cells evading T-cell attack. | Front Immunol | 2025 | 41103411 | PubTator, text mining | PubMed |
| Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway. | EMBO Mol Med | 2025 | 41083822 | PubTator, text mining | PubMed |
| A single-centre, real-world study on the efficacy and recovery of inflammatory cytokine levels of C5 complement inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria. | Br J Haematol | 2025 | 41047870 | PubTator, text mining | PubMed |
| Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies. | Diseases | 2025 | 41002734 | PubTator, text mining | PubMed |
| Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition. | Drugs | 2025 | 40986193 | PubTator, text mining | PubMed |
| Glycosylphosphatidylinositol biosynthesis functions as a conserved host defense pathway against coronaviruses via regulation of LY6E. | PLoS Pathog | 2025 | 40901862 | PubTator, text mining | PubMed |
| Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review. | Clin Exp Med | 2025 | 40886199 | PubTator, text mining | PubMed |
| PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study. | Ann Hematol | 2025 | 40844514 | PubTator, text mining | PubMed |
| Somatic mutations and the efficacy of immunosuppressive therapy in severe/very severe aplastic anemia and transfusion-dependent nonsevere aplastic anemia. | Ann Hematol | 2025 | 40773104 | PubTator, text mining | PubMed |
| Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria. | Health Sci Rep | 2025 | 40661733 | PubTator, text mining | PubMed |
| [Pharmacological characteristics and clinical study results of danicopan (Voydeya® tablets)]. | Nihon Yakurigaku Zasshi | 2025 | 40603035 | PubTator, text mining | PubMed |
| Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape. | Clin Adv Hematol Oncol | 2025 | 40590888 | PubTator, text mining | PubMed |
| Two Cases of Crovalimab-Induced Platelet Recovery in Bone Marrow Failure-Associated Paroxysmal Nocturnal Hemoglobinuria (PNH). | Cureus | 2025 | 40539183 | PubTator, text mining | PubMed |
| RBPJ/PAF1 Signaling Axis Promotes Cloning Expansion in Paroxysmal Nocturnal Hemoglobinuria Through NOTCH Signaling. | Int J Lab Hematol | 2025 | 40501337 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5277/papers?page=2